These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30790602)

  • 21. Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.
    Spertino J; Lopez-Ferrer A; Vilarrasa E; Puig L
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1514-21. PubMed ID: 25493314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab-Induced Psoriasiform Eruption.
    Sladden MJ; Sladden CS; Gulliver WPF
    JAMA Dermatol; 2017 Nov; 153(11):1194-1195. PubMed ID: 28768308
    [No Abstract]   [Full Text] [Related]  

  • 25. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk factors influence response to biological therapies in psoriasis.
    Batalla A; González-Fernández D; González-Lara L; Abalde T; Salgado-Boquete L; Queiro-Silva R; Coto E; Coto-Segura P
    J Am Acad Dermatol; 2015 Aug; 73(2):327-9. PubMed ID: 26183981
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety.
    Khemis A; Kelati A; Montaudié H; Lacour JP; Passeron T
    J Am Acad Dermatol; 2018 Oct; 79(4):758-760. PubMed ID: 29596876
    [No Abstract]   [Full Text] [Related]  

  • 28. Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
    Woo WA; Waite A; Rustin MH; McBride SR
    Br J Dermatol; 2014 Apr; 170(4):989-90. PubMed ID: 24298875
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
    Dogra S; D S K; Budamakuntla L; Srinivas CR; Khopkar U; Gupta S; Shetty N; Pratap DV; Gopal MG; Rao TN; Garg V; Sumathy TK; Saraswat A; Bhat R; Kura M; Pandey N; Shah R; Sai Krishna K; Padmaja D; Manmohan G; M S R; Barve A; Montero E
    J Am Acad Dermatol; 2015 Aug; 73(2):331-3.e1. PubMed ID: 26183983
    [No Abstract]   [Full Text] [Related]  

  • 30. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.
    Wu JJ; Tsai TF
    Arch Dermatol; 2008 Oct; 144(10):1403-4. PubMed ID: 18936418
    [No Abstract]   [Full Text] [Related]  

  • 31. Dose-creep of Infliximab during psoriasis treatment: an observational study.
    Mehren CR; Gniadecki R
    Acta Derm Venereol; 2012 Jul; 92(4):355-7. PubMed ID: 22042041
    [No Abstract]   [Full Text] [Related]  

  • 32. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

  • 33. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.
    Iversen L; Eidsmo L; Austad J; de Rie M; Osmancevic A; Skov L; Talme T; Bachmann I; van de Kerkhof P; Stahle M; Banerjee R; Oliver J; Fasth AER; Frueh J
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1930-1939. PubMed ID: 29633373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
    Galluzzo M; Talamonti M; De Simone C; D'Adamio S; Moretta G; Tambone S; Caldarola G; Fargnoli MC; Peris K; Bianchi L
    Expert Opin Biol Ther; 2018 Jul; 18(7):727-735. PubMed ID: 29798698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 37. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
    Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
    J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.